检索结果 - Floc'h, Nicolas

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer 由 Floc'h, Nicolas, Abate-Shen, Cory

获取全文 获取全文

Modulation of Oxidative Stress by Twist Oncoproteins 由 Floc'h, Nicolas, Kolodziejski, Jakub, Akkari, Leila, Simonin, Yannick, Ansieau, Stéphane, Puisieux, Alain, Hibner, Urszula, Lassus, Patrice

获取全文 获取全文 获取全文

Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response 由 Floc'h, Nicolas, Guerriero, Maria Luisa, Ramos-Montoya, Antonio, Davies, Barry R., Cairns, Jonathan, Karp, Natasha A.

获取全文 获取全文 获取全文

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model 由 Floc'h, Nicolas, Kinkade, Carolyn Waugh, Kobayashi, Takashi, Aytes, Alvaro, Lefebvre, Celine, Mitrofanova, Antonina, Cardiff, Robert D., Califano, Andrea, Shen, Michael M., Abate-Shen, Cory

获取全文 获取全文 获取全文

Lymphotoxin Signaling Is Initiated by the Viral Polymerase in HCV-linked Tumorigenesis 由 Simonin, Yannick, Vegna, Serena, Akkari, Leila, Grégoire, Damien, Antoine, Etienne, Piette, Jacques, Floc'h, Nicolas, Lassus, Patrice, Yu, Guann-Yi, Rosenberg, Arielle R., Karin, Michael, Durantel, David, Hibner, Urszula

获取全文 获取全文 获取全文

B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer 由 Wang, Jingqiang, Kobayashi, Takashi, Floc'h, Nicolas, Kinkade, Carolyn Waugh, Aytes, Alvaro, Dankort, David, Lefebvre, Celine, Mitrofanova, Antonina, Cardiff, Robert D., McMahon, Martin, Califano, Andrea, Shen, Michael M., Abate-Shen, Cory

获取全文 获取全文 获取全文

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC 由 Tu, Eric, McGlinchey, Kelly, Wang, Jixin, Martin, Philip, Ching, Steven L.K., Floc’h, Nicolas, Kurasawa, James, Starrett, Jacqueline H., Lazdun, Yelena, Wetzel, Leslie, Nuttall, Barrett, Ng, Felicia S.L., Coffman, Karen T., Smith, Paul D., Politi, Katerina, Cooper, Zachary A., Streicher, Katie

获取全文 获取全文 获取全文

Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions 由 Floc’h, Nicolas, Martin, Matthew J., Riess, Jonathan W., Orme, Jonathan P., Staniszewska, Anna D., Menard, Ludovic, Cuomo, Maria Emanuela, O'Neill, Daniel J, Ward, Richard A., Finlay, M. Raymond V., McKerrecher, Darren, Cheng, Mingshan, Vang, Daniel P, Tsai, Rebekah A., Keck, James G., Gandara, David R., Mack, Philip C., Cross, Darren, AE

获取全文 获取全文 获取全文